Impact of Undertreated Antithrombotic Therapy on Adverse Patient Outcomes: A Scientific Statement From the American Heart Association.

Undertreatment of antithrombotic therapy increases adverse outcomes, including ischemic stroke and mortality, in patients with thrombotic conditions, affecting over 50% of cases.

• Why it matters: Addressing undertreatment is critical because it leads to preventable complications and healthcare costs, especially among vulnerable populations with social inequities and misperceptions of bleeding risks.
• What they did: The authors analyzed real-world data and highlighted gaps in care, emphasizing the need for structured antithrombotic stewardship and interdisciplinary collaboration to improve adherence and dosing.
• The result: Implementing evidence-based, team-driven strategies can significantly reduce undertreatment, improve patient safety, and close disparities in thrombotic disease management.